REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot170710.32687/1561-5936-2024-28-2-109-119Original ArticleClinical and economic evaluation of the use of favipiravir in treatment regimens for COVID-19KrysanovIvan S.krysanov-ivan@mail.ruGurevichKonstantin G.kgurevich@mail.ruMatveevaNatalia V.matveevanatasha@gmail.comMatveevAlexander V.avmcsmu@gmail.comZaslavskayaKira Ya.kiryonok@yandex.ruKrysanovaVera S.krysanovavs@mgupp.ruErmakovaVictoria Yu.ermakova.viktoriya.yurievna@mail.ruKurkinDenis V.strannik986@mail.ruBalykovaLarisa A.larisabalykova@yandex.ruBelyiPetr A.pbely@ncpharm.ruZemskovDmitry N.dizem1978@gmail.comMakarovaEkaterina V.rue-royal@inbox.ruRussian University of Medicine, Moscow, RussiaRussian Biotechnological University, Moscow, RussiaV. I. Vernadsky Crimean Federal University, Simferopol, RussiaRussian Medical Academy of Continuing Professional Education, Moscow, RussiaNational Research Mordovian State University named after N. P. Ogarev, Saransk, RussiaI. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia15122024210911915102025Copyright © 2024,2024Background. Currently, sufficient information has been accumulated the literature on the clinical effectiveness and safety of favipiravir in adult patients with COVID-19, including cases of its use in intensive care units and in comorbid patients. This article summarizes the latest published data from clinical studies, systematic reviews and meta-analyses, including data from real-life clinical practice. A number of studies have conducted a pharmacoeconomic evaluation of the use of favipiravir in adult patients with COVID-19. Objective. To evaluate pharmacoeconomic efficacy of the use of favipiravir in adult patients with non-severe forms of COVID-19 in a Russian hospital settings. Materials and methods. On the basis of the clinic of the Russian University of Medicine a non-interventional clinical study was performed, including 201 patients with mild COVID-19. Patients were divided into two groups: with favipiravir therapy or without it. Results. A reduction in hospitalization time by 2 days was demonstrated in patients with COVID-19 receiving favipiravir, which leads to the reduction in hospitalization costs for 1 patient in the amount of RUB 16,643.69. Conclusions. Thus, various data on the use of favipiravir for COVID-19 allow us to demonstrate pharmacoeconomic benefits, both in terms of budgetary savings and a positive impact on reducing the burden on the healthcare system and improving key medical statistics, including morbidity and mortality.favipiravirCOVID-19expensesefficiencysafetytreatment regimensreviewфавипиравирCOVID-19затратыэффективностьбезопасностьсхемы леченияобзор[Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) 17th ed., Moscow, 2022. 260 p. (In Russ.)][Furuta Y., Komeno T., Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn Acad. Ser. B Phys. Biol. Sci. 2017;93(7):449–463. DOI: 10.2183/pjab.93.027][Shrestha D. B., Budhathoki P., Khadka S. et al. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol. J. 2020;17(1):141. DOI: 10.1186/s12985-020-01412-z][Prakash A., Singh H., Kaur H. et al. Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients. Indian J. Pharmacol. 2020;52(5):414–421. DOI: 10.4103/ijp.ijp_998_20][Manabe T., Kambayashi D., Akatsu H., Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect. Dis. 2021;21(1):489. DOI: 10.1186/s12879-021-06164-x][Hassanipour S., Arab-Zozani M., Amani B. et al. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci. Rep. 2021;11(1):11022. DOI: 10.1038/s41598-021-90551-6][Özlüşen B., Kozan Ş., Akcan R. E. et al. Effectiveness of favipiravir in COVID-19: a live systematic review. Eur. J. Clin. Microbiol. Infect. Dis. 2021;40(12):2575–2583. DOI: 10.1007/s10096-021-04307-1][Qomara W. F., Primanissa D. N., Amalia S. H. et al. Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 treatment: a systematic review. Int. J. Gen. Med. 2021;14:8557–8571. DOI: 10.2147/IJGM.S332458][Gil Martínez V., Avedillo Salas A., Santander Ballestín S. Antiviral therapeutic approaches for SARS-CoV-2 infection: a systematic review. Pharmaceuticals (Basel). 2021. Vol. 14(8):736. DOI: 10.3390/ph14080736][Udwadia Z. F., Singh P., Barkate H. et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int. J. Infect. Dis. 2021;103:62–71. DOI: 10.1016/j.ijid.2020.11.142][Balykova L. A., Radaeva O. A., Zaslavskaya K. Y. et al. Study of clinical and pathogenetic effects of anti-viral drug based on favipiravir in comorbid patients with COVID-19 at the outpatient stage of treatment. Pharmacy & Pharmacology. 2021;9(6):454–464. (In Russ.) DOI: 10.19163/2307-9266-2021-9-6-454-464][Chen C., Zhang Y., Huang J. et al. Favipiravir versus Arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: a prospective, multicenter, open-label, randomized controlled clinical trial. Front Pharmacol. 2021;12:683296. DOI: 10.3389/fphar.2021.683296][Doi Y., Hibino M., Hase R. et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob. Agents Chemother. 2020;64(12):e01897–e01920. DOI: 10.1128/AAC.01897-20][Agrawal U., Raju R., Udwadia Z. F. Favipiravir: a new and emerging antiviral option in COVID-14. Med. J. Armed Forces India. 2020;76(4):370–376. DOI: 10.1016/j.mjafi.2020.08.004][Ivashchenko A. A., Dmitriev K. A., Vostokova N. V. et al. Avifavir for treatment of patients with moderate Coronavirus Disease 2019 (COVID-19): interim results of a phase II/III multicenter randomized clinical trial. Clin. Infect. Dis. 2021;73(3):531–534. DOI: 10.1093/cid/ciaa1176][Balykova L. A., Govorov A. V., Vasilyev A. O. et al. Characteristics of COVID-19 and possibilities of early causal therapy. Results of favipiravir use in clinical practice. Infectious diseases. 2020;18(3):30–40. (In Russ.) DOI: 10.20953/1729-9225-2020-3-30-40][Balykova L. A., Pavelkina V. F., Shmyreva N. V. et al. Efficacy and safety of some etiotropic therapeutic schemes for treating patients with novel coronavirus infection (COVID-19). Pharmacy & Pharmacology. 2020;8(3):150–159. (In Russ.) DOI: 10.19163/2307-9266-2020-8-3-150-159][Ruzhentsova T. A., Chukhliaev P. V., Khavkina D. A. et al. Potential for etiotropic therapy of SARSCoV-2-induced coronavirus disease in outpatients. Medical Opponent. 2020;1(9):48–58. In Russ.)][Pilkington V., Pepperrell T., Hill A. A review of the safety of favipiravir — a potential treatment in the COVID-19 pandemic? J. Virus Erad. 2020;6(2):45–51. DOI: 10.1016/S2055-6640(20)30016-9][Kumagai Y., Murakawa Y., Hasunuma T. et al. Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults. Int. J. Clin. Pharmacol. Ther. 2015;53(10):866–874. DOI: 10.5414/CP202388][Shiraki K., Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol. Ther. 2020;209:107512. DOI: 10.1016/j.pharmthera.2020.107512]